SCHEMBL1713164

SCHEMBL1713164

O=Cc1ccc(Oc2cnc(C3CC3)nc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.47
▸ KDM4E B2RXH2 5/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ LMNA P02545 2/20 0.47
▸ PARP10 Q53GL7 1/20 0.42
▸ PARP3 Q9Y6F1 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ CASP6 P55212 1/20 0.41
▸ CYP2A6 P11509 1/20 0.39
▸ ALDH1A3 P47895 1/20 0.36
▸ STS P08842 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ HPGD P15428 1/20 0.34
▸ HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5008896 0.78 HDAC4 (0.33) HDAC4
SCHEMBL15129512 0.77 HDAC4 (0.35) ALDH1A1KDM4EL3MBTL1HDAC4
SCHEMBL1713491 0.76 KDM4E (0.54) ALDH1A1KDM4ESMN1; SMN2LMNAPARP10
SCHEMBL1663469 0.74 PARP10 (0.65) ALDH1A1KDM4ESMN1; SMN2LMNAPARP10
SCHEMBL5050902 0.74 PARP10 (0.65) ALDH1A1KDM4ESMN1; SMN2LMNAPARP10
SCHEMBL16761850 0.74 ALDH1A1 (0.56) ALDH1A1KDM4ESMN1; SMN2LMNAPARP10
SCHEMBL31621330 0.73 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2LMNAPARP10
SCHEMBL31621333 0.73 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2LMNAPARP10
SCHEMBL876578 0.72 ALDH1A1 (0.49) ALDH1A1KDM4ESMN1; SMN2LMNAPARP10
SCHEMBL1713688 0.72 KDM4E (0.50) ALDH1A1KDM4ESMN1; SMN2LMNAPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232101-A1 Novel Compounds CHAPMAN DAVID (SE) 2012-09-13 — — US disclosed
US-8183251-B2 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease ASTRAZENECA AB (SE) 2012-05-22 — — US disclosed
EP-2097406-B1 HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS ASTRAZENECA AB (SE) 2011-07-20 — — EP disclosed
EP-2097406-A1 HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS Astra Zeneca AB (SE) 2009-09-09 — — EP disclosed
US-20080221139-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-09-11 — — US disclosed
WO-2008065393-A1 HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS ASTRAZENECA AB (SE) 2008-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221139-A1 Novel Compounds MMP9, MMP2, MMP1 ALDH1A1 282/4885KDM4E 1320/4885SMN1; SMN2 1975/4885
US-20120232101-A1 Novel Compounds MMP9, MMP2, MMP1 ALDH1A1 282/4885KDM4E 1320/4885SMN1; SMN2 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback